Skip to main content
Toggle navigation
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Red Recording
Sig Meeting
Like
Tweet
Print
Brett L. Dabruzzo, PharmD
AbbVie
Poster(s):
(T 5) Weight Loss With Atogepant Versus Topiramate: Post hoc Analysis of the Head-to-Head TEMPLE Trial
(E 55) Real-World Migraine Treatment Patterns in the Era of CGRP-Targeted Therapies: Low Preventive Uptake and Dynamic Regimen Shifts: A Retrospective Claims Analysis
(T 11) Effect of Adding Atogepant to OnabotulinumtoxinA on Symptoms-Free Days: Results from a Phase 3, Multicenter, 24-Week Open-Label Study (UNCHAINED)
(T 13) Blood Pressure Changes With Atogepant in Overweight and Obese Persons With Migraine and Baseline Hypertension: Interim Analysis of a Phase 3, Multicenter, Open-label, 156-Week Extension Study
